Search clinical trials for: Erlotinib Sirolimus

Total 2489 results

Duke University
Genentech, Inc.; OSI Pharmaceuticals

Completed

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Glioblastoma | Gliosarcoma

United States
Jonsson Comprehensive Cancer Center

Completed

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Masaryk University

Unknown

Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction (ROBUST)

Coronary Heart Disease | Percutaneous Coronary Intervention

Czech Republic
Biosensors Europe SA

Unknown

BioFreedom QCA Study in CAD Patients (BioFreedomQCA)

Myocardial Infarction | Coronary Artery Disease | Cardiac Death

Spain, Denmark
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Translational Research Center for Medical Innovation...
Wakayama Medical University

Completed

OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON (OPINION)

Coronary Artery Disease

Japan
Theodore Laetsch

Terminated

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Relapsed / Recurrent Germ Cell Tumors

United States
University of Colorado, Denver
Genentech, Inc.

Completed

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Columbia University
Wyeth is now a wholly owned subsidiary of Pfizer; Genentech, Inc.

Completed

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Triple Negative Breast Cancer

United States
Washington University School of Medicine
Pfizer

Completed

Erlotinib and Temsirolimus for Solid Tumors

Solid Tumors

United States
Duke University
Genentech, Inc.

Completed

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Glioblastoma | Gliosarcoma

United States
New Mexico Cancer Care Alliance
Genentech, Inc.

Terminated

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Squamous Cell Carcinoma

United States
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
Terumo Europe N.V.

Completed

Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients (TROFI)

Myocardial Infarction | Coronary Artery Disease | STEMI

Germany, France, Denmark, Netherlands
National Cancer Institute (NCI)

Completed

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma | Recurrent Adult Brain Tumor | Adult Subependymal Giant...

United States
Odense University Hospital

Unknown

Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent (SORT OUT VII)

Coronary Artery Disease | Ischemic Heart Disease

Denmark
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Translational Research Center for Medical Innovation...
Wakayama Medical University

Completed

OPtical Frequency Domain Imaging Versus INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging

Coronary Artery Disease

Japan
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
M.D. Anderson Cancer Center

Completed

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Advanced Cancers

United States
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Merck Sharp & Dohme LLC

Completed

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Carcinoma, Non-small Cell Lung
University of Chicago
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Malignant Peritoneal Mesothelioma

United States
New Mexico Cancer Care Alliance

Completed

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Advanced Solid Tumor Malignancies

United States
Duke University
Bristol-Myers Squibb; Genentech, Inc.

Completed

Ph I Dasatinib + Erlotinib in Recurrent MG

Glioblastoma | Gliosarcoma

United States
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (TP2001-201)

Recurrent Non Small Cell Lung Cancer

United States
Grupo de Investigación Clínica en Oncología Radioterapia

Completed

Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Spain
Sidney Kimmel Cancer Center at Thomas Jefferson...
Genentech, Inc.

Completed

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

Carcinoma, Non-small-cell Lung

United States
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer

United States
PharmaMar

Completed

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

Spain, United States
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
University of California, Davis
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Non Small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Carcinoma, Non-small-cell Lung
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Recurrent Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Bladder Cancer | Stage IV Bladder Cancer | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage III Esophageal Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Grade III Meningioma

United States
Hospital Arnau de Vilanova

Unknown

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Non-Small Cell Lung Cancer

Spain
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Paraganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, Malignant

China
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China

Search clinical trials for: Erlotinib Sirolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations